Skye Bioscience, Inc. (SKYE)
1.77
-0.07
(-3.80%)
USD |
NASDAQ |
Sep 03, 16:00
1.88
+0.11
(+6.21%)
After-Hours: 20:00
Skye Bioscience Research and Development Expense (TTM) : 32.02M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 32.02M |
| March 31, 2026 | 42.38M |
| December 31, 2025 | 41.64M |
| September 30, 2025 | 38.14M |
| June 30, 2025 | 33.85M |
| March 31, 2025 | 23.78M |
| December 31, 2024 | 18.70M |
| September 30, 2024 | 12.50M |
| June 30, 2024 | 8.871M |
| March 31, 2024 | 6.581M |
| December 31, 2023 | 5.820M |
| September 30, 2023 | 5.734M |
| June 30, 2023 | 6.261M |
| March 31, 2023 | 5.900M |
| December 31, 2022 | 5.980M |
| September 30, 2022 | 5.588M |
| June 30, 2022 | 4.134M |
| March 31, 2022 | 3.587M |
| December 31, 2021 | 2.930M |
| September 30, 2021 | 2.186M |
| June 30, 2021 | 2.204M |
| March 31, 2021 | 1.752M |
| December 31, 2020 | 1.942M |
| September 30, 2020 | 2.289M |
| June 30, 2020 | 2.456M |
| Date | Value |
|---|---|
| March 31, 2020 | 2.716M |
| December 31, 2019 | 2.237M |
| September 30, 2019 | 1.759M |
| June 30, 2019 | 1.314M |
| March 31, 2019 | 0.626M |
| December 31, 2018 | 0.33M |
| September 30, 2018 | 0.1623M |
| June 30, 2018 | 0.1836M |
| March 31, 2018 | 0.2442M |
| December 31, 2017 | 0.3113M |
| September 30, 2017 | 0.5045M |
| June 30, 2017 | 0.4965M |
| March 31, 2017 | 0.8958M |
| December 31, 2016 | 0.939M |
| September 30, 2016 | 1.019M |
| June 30, 2016 | 1.091M |
| March 31, 2016 | 0.6743M |
| December 31, 2015 | 0.5761M |
| September 30, 2015 | 0.2654M |
| June 30, 2015 | 0.3081M |
| March 31, 2015 | 0.2647M |
| December 31, 2014 | 0.2275M |
| September 30, 2014 | 0.195M |
| April 30, 2014 | 0.00 |
| January 31, 2014 | 0.00 |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Regeneron Pharmaceuticals, Inc. | 5.748B |
| Viking Therapeutics, Inc. | 509.32M |
| ACADIA Pharmaceuticals, Inc. | 331.01M |
| Alnylam Pharmaceuticals, Inc. | 1.509B |
| Anika Therapeutics, Inc. | 27.45M |